4 results on '"Yaohong LIU"'
Search Results
2. Effects of deficient mismatch repair on the prognosis of patients with stage II and stage III colon cancer during different postoperative periods
- Author
-
Chunze Zhang, Yixiang Zhan, Kemin Ni, Zhaoce Liu, Ran Xin, Qiurong Han, Guoxun Li, Hangyu Ping, Yaohong Liu, Xuanzhu Zhao, Wanting Wang, Suying Yan, Jing Sun, Qinghuai Zhang, Guihua Wang, Zili Zhang, Xipeng Zhang, and Xia Hu
- Subjects
Male ,Cancer Research ,Prognosis ,DNA Mismatch Repair ,Oncology ,Testicular Neoplasms ,Chemotherapy, Adjuvant ,Antineoplastic Combined Chemotherapy Protocols ,Colonic Neoplasms ,Genetics ,Humans ,Fluorouracil ,Postoperative Period ,Aged ,Retrospective Studies ,Neoplasm Staging - Abstract
Background We evaluated the prognostic role of deficient mismatch repair (dMMR) systems in stage II and stage III colon cancer patients during different postoperative periods. We also assessed whether patients aged ≥75 could benefit from chemotherapy. Methods This retrospective study was conducted across three medical centers in China. Kaplan–Meier survival methods and Cox proportional hazards models were used to evaluate the differences in overall survival (OS) and disease-free survival (DFS) rates. Propensity score matching was performed to reduce imbalances in the baseline characteristics of the patients. Landmark analysis was performed to evaluate the role of dMMR during different postoperative periods. Results The median follow-up time for all patients was 45.0 months (25–75 IQR: 38.0–82.5). There was no significant OS (p = 0.350) or DFS (p = 0.752) benefit associated with dMMR for stage II and III patients during the first postoperative year. However, significant OS (p p p = 0.341) or DFS (HR = 0.98, 95% CI: 0.51–1.88, p = 0.961) benefit for patients aged ≥75 years. Conclusion The benefits of dMMR in stage III patients were observed from the second postoperative year until the end of follow-up. However, the prognosis of patients with dMMR is not different from that of patients with proficient mismatch repair (pMMR) during the first postoperative year. In addition, elderly patients aged ≥75 years obtained no significant survival benefits from postoperative chemotherapy.
- Published
- 2022
3. Efficacy and Safety of CalliSpheres® Drug-Eluting Beads Transarterial Chemoembolization in Barcelona Clinic Liver Cancer Stage C Patients
- Author
-
Yongjian Guo, Kangshun Zhu, Jingjun Huang, Hui Lian, Wensou Huang, Mingji He, Yaohong Liu, and Jingwen Zhou
- Subjects
0301 basic medicine ,Cancer Research ,medicine.medical_specialty ,Bilirubin ,Nausea ,Gastroenterology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,Carcinoma ,Medicine ,Adverse effect ,business.industry ,General Medicine ,medicine.disease ,BCLC Stage ,030104 developmental biology ,Oncology ,chemistry ,030220 oncology & carcinogenesis ,Vomiting ,medicine.symptom ,business ,Liver cancer ,TBIL - Abstract
This study aimed to investigate the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) treatment in Barcelona Clinic Liver Cancer (BCLC) stage C liver cancer patients. In 39 patients with BCLC stage C liver cancer, after the first cycle of DEB-TACE, 2 (5.1%) and 24 (61.5%) patients achieved complete response (CR) and partial response (PR) to give an overall objective response rate (ORR) of 66.7%. With respect to the second cycle of therapy, the ORR was higher in patients receiving DEB-TACE compared with those receiving cTACE (57.1% vs. 11.1%). After the first cycle of DEB-TACE treatment, the percentages of abnormal albumin (ALB), total protein (TP), total bilirubin (TBIL), and alanine aminotransferase (ALT) worsened at 1 week and recovered at 1 month. The number of patients with abnormal aspartate aminotransferase (AST) did not increase at 1 week but elevated at 1 month. After the second cycle of DEB-TACE or cTACE treatment, no difference was observed between cTACE and DEB-TACE in terms of all adverse events (AEs) at all visits, and most of the AEs did not change after the second cycle in both groups. The most common AEs after the first and second treatment cycles were pain, fever, and nausea/vomiting. These results demonstrate that DEB-TACE offers patients with BCLC stage C liver cancer a clinically active short-term treatment that is safe and relatively well tolerated.
- Published
- 2019
4. LncRNA DLEU2 aggravates the progression of hepatocellular carcinoma through binding to EZH2
- Author
-
Yongcheng An, Liteng Lin, Licong Liang, Yaohong Liu, Jingjun Huang, Mingjun Bai, Wensou Huang, and Yongjian Guo
- Subjects
Male ,0301 basic medicine ,DLEU2 ,Carcinoma, Hepatocellular ,Immunoprecipitation ,Proliferation ,RNA-binding protein ,RM1-950 ,Biology ,03 medical and health sciences ,0302 clinical medicine ,Downregulation and upregulation ,Invasion ,Cell Movement ,Cell Line, Tumor ,medicine ,Humans ,Enhancer of Zeste Homolog 2 Protein ,Neoplasm Invasiveness ,EZH2 ,HCC ,Enhancer ,Migration ,Cell Proliferation ,Pharmacology ,Gene knockdown ,Liver Neoplasms ,General Medicine ,Middle Aged ,medicine.disease ,digestive system diseases ,Up-Regulation ,Gene Expression Regulation, Neoplastic ,Leukemia ,030104 developmental biology ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Disease Progression ,Cancer research ,Female ,RNA, Long Noncoding ,Therapeutics. Pharmacology ,Protein Binding - Abstract
To explore whether lncRNA deleted in lymphocytic leukemia 2 (DLEU2) could accelerate the migratory, invasive and proliferative abilities, thus influencing the progression of HCC. DLEU2 level in HCC tissues and adjacent normal tissues was firstly determined. Its level in HCC tissues with different tumor sizes (≤ 5 cm or > 5 cm), different tumor stages (stage I-II or III-IV) and either with vascular invasion or not was determined. Potential influences of DLEU2 on proliferative, migratory and invasive abilities of SMMC7721 and HCLM3 cells were assessed. The interaction between DLUE2 and enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) was evaluated by RNA Binding Protein Immunoprecipitation (RIP) assay. Finally, the effect of DLEU2/EZH2 regulatory loop on proliferative ability of HCC cells was detected. DLEU2 was upregulated in HCC tissues, especially in those larger than 5 cm in tumor size, accompanied with vascular invasion and in worse tumor stage. Knockdown of DLEU2 attenuated proliferative, migratory and invasive abilities of SMMC7721 and HCLM3 cells. RIP assay proved that DLEU2 could interact with EZH2. Knockdown of EZH2 attenuated the inhibited proliferation in HCC cells with DLEU2 knockdown. DLEU2 accelerates the proliferative, migratory and invasive abilities of HCC cells via binding to EZH2, thus aggravating the progression of HCC.
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.